Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARLiT: Pluvicto and SBRT in Locally Advanced Prostate Cancer
NCT06574880Phase 2Recruiting
- Start
- May 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa). Started May 2025; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06574880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06574880.